Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “PHARMACEUTICALS”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 307 records · Page 17

Transforming Biological Science and Biomedical Practice

Opioid overdoses killed more than 50,000 people in the U.S. in 2016, reaching epidemic proportions. New opioid drugs that suppress pain but are neither addictive nor likely to cause overdose deaths are now in the pharmaceutical pipeline, the result of decades of research into how medicines attach to and communicate with the body’s cells. Critical to that research was a new method of determining the structure of large biological molecules, using extremely powerful beams of X-rays developed and supported at shared research facilities by the Basic Energy Sciences (BES) office of DOE. Such X-ray studies are now central to new drug development: the BES facilities are used by the pharmaceutical industry to screen most new drug candidates.

59 BASIC BIOLOGICAL SCIENCES↗

Recent upgrades and new scientific infrastructure of MARIA research reactor, Otwock-Swierk, Poland

The MARIA reactor is open-pool type, water and beryllium moderated. It has two independent primary cooling systems: fuel and pool cooling system. Each fuel assembly is cooled down separately in pressurized channels with individual performances characterization. The fuel assemblies consist of five layers of bent plates or six concentric tubes. Currently it is one of the most powerful research reactors in Europe with operation availability at least up to 2030. Its nominal thermal power is 30 MW. It is characterized by high neutron flux density: up to 3x10{sup 14} n cm{sup -2} s{sup -1} in case of thermal neutrons, and up to 2x10{sup 13} n cm{sup -2} s{sup -1} in case of fast neutrons. The reactor is operated for ca. 4000 h per year. The reactor facility is equipped with fully equipped three hot cells with shielding up to 10{sup 15} Bq. Adjacent to the reactor facility, the radio-pharmaceutics plant (POLATOM) and Material Research Laboratory are located. They are equipped with a number of hot cells with instrumentation. The transport system of radioactive materials from reactor facility to Material Research Laboratory is available. During 2014 the MARIA reactor has been operated with three different types of fuel the same time: previous 36% enriched fuel, and two types of new LEU fuels. In the meantime, molybdenum irradiation programme has been developed. Maria is a multifunctional research tool, with a notable application in production of radioisotopes, radio-pharmaceutics manufacturing (ca. 600 TBq/y), {sup 99}Mo for medical scintigraphy (ca. 6000 TBq/y), neutron transmutation doping of silicon single crystals, wide scientific research based on neutron beams utilization. From the beginning MARIA reactor was intended for loop and fuel testing research activities. Currently it is used mostly as material testing and irradiation facility and for that reason it has wide experimental capabilities. There are eight horizontal irradiation channels from among whom six of them are equipped with instrumentation for condensed matter physics research: - H3 - spectrometer and diffractometer with double monochromator; - H4 - small angle scattering spectrometer; - H5 - polarized neutrons spectrometer; - H6, H7 - two 3-axial crystal neutron spectrometers; - H8 - neutron radiography stand. For two horizontal channels are ongoing exploitation programs: - H2 - station with epithermal neutron beam produced in uranium converter is being developed. Intelligent converter will be installed on the periphery of reactor core. The intensity of the beam will be at the level 2x10{sup 9} n cm{sup -2}s{sup -1} what makes the beam unique in the Europe. - H1 - special pneumatic horizontal mail is being developed for irradiation material samples in the vicinity of the core i.e. in the distal part of the H1 channel. The number of neutron irradiation facilities in MARIA reactor is increasing every year. Numerous of thermal neutron irradiation channels including fast hydraulic rabbit system and large size channels for fast neutron irradiation are used routinely. Recently new in-pile facility with ITER-like neutron energy spectrum for 14 MeV neutron irradiation has been constructed. Taking into account its performance and ability of almost incessant operation the facility appears as one of the most powerful 14 MeV neutron sources. The facility shall be used for material research connected with thermonuclear devices (ITER) and 4. generation nuclear reactors. The system of independent fuels channels used in MARIA reactor appear to be very flexible and very convenient to be used as irradiation channels for uranium targets for {sup 99}Mo production. Currently, MARIA reactor supplies ca. 18% world production of {sup 99}Mo. The MARIA reactor research activities are still extended. The current scientific projects are connected e.g. with silicon neutron transmutation doping, in-pile gamma heating measurements, French calculation codes implementation (TRIPOLI4, APOLLO2). The horizontal neutron beams utilization is also developed. The MARIA reactor, due to its primary application connected with loop and fuel testing, is very convenient for testing the nuclear instrumentation, control and measurement systems.

21 SPECIFIC NUCLEAR REACTORS AND ASSOCIATED PLANTS↗

Decontamination and Decommissioning Program of a Radiopharmaceuticals Production Facility - 17103

On May 2012, Best Medical Belgium (BMB) S.A., a manufacturer of pharmaceutical products located on the nuclear site of Fleurus, was declared bankrupt. According to the Belgian law, ONDRAF/NIRAS (Belgian Radioactive Waste Management Agency) was entrusted with the clean-up and the decommissioning operations of the former BMB facilities, nowadays known as 'ONDRAF/NIRAS Site Fleurus' (ONSF). In June 2015, ONSF launched a Decontamination and Decommissioning (D and D) program, for which Tractebel supports the definition of the clean-up and decommissioning strategies; the drafting of the Final Decommissioning Plan (FDP) and License Application for decommissioning; and the follow-up of the clean-up and upcoming D and D works on site. Four nuclear buildings are part of the clean-up and D and D activities. One of them, Building 14 (B14), represents the most challenging task with the clean-up of highly contaminated areas and their further decommissioning up to greenfield. Beside its two cyclotrons successively used for the production of radioisotopes, this building features hot cells and glove boxes used for the purification of radioisotopes and the conditioning of the final pharmaceutical product. The present paper aims at presenting the development of the D and D program in terms of modifications of existing facilities to allow carrying out the clean-up and D and D activities and the management of dismantled radioactive materials in a safe, efficient and cost-effective way as well as in terms of strategic options to be developed for the FDP. To support the clean-up and D and D activities, several workshops have been designed in order to treat radioactive materials removed from the building rooms. Those workshops feature an input buffer storage area, a common output buffer storage area and installations for the treatment of radioactive materials and waste (handling devices, cutting means, decontamination means, free release measurements means, etc.). Some modifications to the existing auxiliary systems will be required in order to dispose of appropriate systems to operate those workshops in a safe way. Activated concrete structures will constitute the most important part of radioactive materials that will arise from the decommissioning activities. To limit the total decommissioning costs, and especially the costs associated to radioactive waste management, two strategies have been developed in order to manage a part of activated concrete as candidate for free release with a certain decay period or as candidate for conventional landfill. Both strategies will have to be further detailed and discussed with the competent Authorities to ensure they can actually be implemented. (authors)

12 MANAGEMENT OF RADIOACTIVE AND NON-RADIOACTIVE W↗

Decontamination and Decommissioning Activities of a Radiopharmaceuticals Production Facility - 18067

On May 2012, Best Medical Belgium S.A. (BMB), a manufacturer of pharmaceutical products located on the nuclear site of Fleurus, was declared bankrupt. According to the Belgian law, ONDRAF/NIRAS (Belgian Radioactive Waste Management Agency) was entrusted with the clean-up and decommissioning operations of the former BMB facilities, nowadays known as 'ONDRAF Site Fleurus' (ONSF). In June 2015, ONSF launched a Decontamination and Decommissioning (D and D) program, for which Tractebel: - Supports the definition of the clean-up and decommissioning strategies; - Drafts the Final Decommissioning Plan (FDP) and Safety Analysis Report (SAR) that will be submitted to FANC/AFCN (Belgian Federal Agency for Nuclear Control) in order to get the License for decommissioning; - Drafts the technical specifications of the public tendering process related to the D and D program; - Ensures the day to-day follow-up of the D and D activities on site. Four nuclear buildings are part of the D and D activities. One of them, building 14 (B14), represents the most challenging and extensive task with the clean-up of highly contaminated areas and its further decommissioning up to the final state. This building features two cyclotrons (CGR and IBA cyclotrons) successively used to produce radioisotopes, as well as hot cells and glove boxes used for their purification and the conditioning of the final pharmaceutical product. The present paper aims at presenting the most recent development steps of the clean-up phase regarding the adaptations of existing facilities and the upcoming activities in preparation of the decommissioning activities. To allow the sorting and the treatment of the radioactive material identified in the physical and radiological inventory, several workshops have been implemented within the B14 building in order to deal with radioactive materials arising from the clean-up and D and D activities. Following the conceptual design phase, Tractebel has actively monitored the on-site activities for the construction of those workshops such as: - The modification of the civil works; - The revamping of the ventilation system; - The installation of dedicated lifting equipment and workstations equipped with cutting devices; - The assembly of a docking station for filling the radioactive packages. The removal of the activated concrete surrounding the IBA cyclotron requires the erection of a containment structure and an extension structure. The containment structure, composed of light metallic beams, is located above the cyclotron and its irradiation zones. For operational security reasons and working efficiency, the cutting process of the concrete ceilings and walls will be performed from the top inside the containment structure by means of an eight tons overhead bridge crane. Concrete blocks resulting from the cutting process will then be lifted, without any loss of containment, towards the extension zone of the nuclear zone of the IBA cyclotron for further resizing, sorting and evacuation towards the identified waste routes. To prepare this task which will be performed during the decommissioning phase, Tractebel sets up the necessary technical specifications. (authors)

12 MANAGEMENT OF RADIOACTIVE AND NON-RADIOACTIVE W↗

Can we stop the spread of influenza in schools with face masks?

In the absence of a strain-specific vaccine and the potential resistance to antiviral medication, nonpharmaceutical interventions can be used to reduce the spread of an infectious disease such as influenza. The most common non-pharmaceutical interventions include school closures, travel restrictions, social distancing, enforced or volunteer home isolation and quarantine, improved hand hygiene, and the appropriate wearing of face masks. However, for some of these interventions, there are some unavoidable economic costs to both employees and employers, as well as possible additional detriment to society as a whole. For example, it has been shown that school-age children are most likely to be infected and act as sources of infection for others, due to their greater societal interaction and increased susceptibility. Therefore, preventing or at least reducing infections in children is a logical first-line of defense. For this reason, school closures have been widely investigated and recommended as part of pandemic influenza preparedness, and some studies support this conclusion. Yet, school closures would result in lost work days if at least one parent must be absent from work to care for children who would otherwise be at school. In addition, the delay in-academic progress may be detrimental due to mass school absenteeism. In particular, the pandemic influenza guidance by the U.S. Department of Health and Human Services recommends school closures for less than four weeks for Category 2 and 3 pandemics (i.e., similar to the milder 1957 and 1968 pandemics) and one to three months for Category 4 and 5 pandemics (i .e., similar to the 1918 pandemic ). Yet, given the above, it is clear that closing schools for up to three months is unlikely to be a practical mitigation strategy for many families and society. Thus modelers and policy makers need to weigh all factors before recommending such drastic measures, particularly if the agent under consideration typically has low mortality and causes a mild disease. Therefore, we contend that face masks are an effective, practical, non-pharmaceutical intervention that would reduce the spread of disease among school-children, while keeping schools open. Influenza spreads through person-to-person contact, via transmission by large droplets or aerosols (droplet nuclei) produced by breathing, talking, coughing or sneezing, as well as by direct (though most people touch very few others in their daily lives) or indirect (i.e., via fomites) contact. Face masks act as a physical barrier to reduce the amount of potentially infectious inhaled and exhaled particles, although they would not reliably protect the wearer against aerosols; a recent study also demonstrated that they can redirect and decelerate exhaled airflows (when worn by an infected individual) to prevent them from entering the breathing zones of others. Thus, if a whole classroom were to don face masks, disease transmission would be expected to be greatly diminished. Another recent study on face masks and hand hygiene show a 10-50% transmission reduction for influenza-like illnesses. Furthermore, face masks can act as an effective physical reminder and barrier to transmission by preventing the wearer from touching any potentially infectious secretions from their mucous membranes (i.e., from the nose and mouth), which is another mechanism for direct and indirect contact transmission for influenza. A recent systematic review has suggested that wearing masks can be highly effective in limiting the transmission of respiratory infections, such as influenza. Yet, admittedly, the effectiveness of this intervention strategy is highly dependent on compliance (i.e., the willingness to wear the mask in all appropriate situations), which in tum depends on comfort, convenience, fitness, and hygiene. Importantly, masks themselves must not become a source of infection (or reinfection); as such they should be replaced or sanitized daily (where possible) to maximize effectiveness. One solution could be for masks to be touted as fashion accessories, which may be particularly effective in influencing trend-conscious children. With support from the fashion industry and a child-targeted public health campaign, it may be possible to encourage such a trend and make the mask an acceptable fashion item, as well as an important means of infectious disease control.

57↗

Towards renewable flavors, fragrances, and beyond

Esters demand a large space of unique molecules with broad range of applications as flavors, fragrances, pharmaceuticals, cosmetics, green solvents, and advanced biofuels. Global demand of natural esters in food, household cleaner, personal care, and perfume industries is increasing while the ester supply from natural sources has been limited. Development of novel microbial cell factories for ester production from renewable feedstocks can potentially provide an alternative and sustainable source of natural esters and hence help fulfill growing demand. In this work, we highlight recent advances in microbial production of esters and provide perspectives for improving its economic feasibility. As the field matures, microbial ester production platforms will enable renewable and sustainable production of flavors, fragrances, and open new market opportunities beyond what nature can offer.

59 BASIC BIOLOGICAL SCIENCES↗

Bioinspired Diversification Approach Toward the Total Synthesis of Lycodine-Type Alkaloids

Nitrogen heterocycles (azacycles) are common structural motifs in numerous pharmaceuticals, agrochemicals, and natural products. Many powerful methods have been developed and continue to be advanced for the selective installation and modification of nitrogen heterocycles through C–H functionalization and C–C cleavage approaches, revealing new strategies for the synthesis of targets containing these structural entities. Here, we report the first total syntheses of the lycodine-type Lycopodium alkaloids casuarinine H, lycoplatyrine B, lycoplatyrine A, and lycopladine F as well as the total synthesis of 8,15-dihydrohuperzine A through bioinspired late-stage diversification of a readily accessible common precursor, N-desmethyl-β-obscurine. Key steps in the syntheses include oxidative C–C bond cleavage of a piperidine ring in the core structure of the obscurine intermediate and site-selective C–H borylation of a pyridine nucleus to enable cross-coupling reactions.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗

Preferential nucleation during polymorphic transformations

Polymorphism is the ability of a solid material to exist in more than one phase or crystal structure. Polymorphism may occur in metals, alloys, ceramics, minerals, polymers, and pharmaceutical substances. Unresolved are the conditions for preferential nucleation during polymorphic transformations in which structural relationships or special crystallographic orientation relationships (OR’s) form between the nucleus and surrounding matrix grains. We measured in-situ and simultaneously the nucleation rates of grains that have zero, one, two, three and four special OR’s with the surrounding parent grains. These experiments show a trend in which the activation energy for nucleation becomes smaller – and therefore nucleation more probable - with increasing number of special OR’s. As a result, these insights contribute to steering the processing of polymorphic materials with tailored properties, since preferential nucleation affects which crystal structure forms, the average grain size and texture of the material, and thereby - to a large extent - the final properties of the material.

36 MATERIALS SCIENCE↗

Crystal structure and polymorphic forms of auranofin revisited

Auranofin, initially developed as a treatment for rheumatoid arthritis, is currently under extensive investigation as a potential drug for various conditions, including cancer, bacterial infections, and parasitic infections. The compound is a known inhibitor of thioredoxin reductase (TXNRD1) and related selenoproteins. Although preliminary studies on the auranofin crystal polymorphism exist, and a low-quality crystal structure has been reported, a comprehensive crystallographic characterization remains unexplored. Utilizing X-ray crystallography techniques, we conducted detailed structural analysis of auranofin and compared our findings with related organogold compounds. Implementation of Hirshfeld atom refinement (HAR) enabled a more accurate hydrogen atom positioning in the structure. The crystal packing reveals a layered arrangement stabilised by numerous weak hydrogen bonds and dispersive interactions. Notably, our attempts to reproduce the previously reported polymorphic form of auranofin, purportedly more water-soluble, were unsuccessful despite following published protocols. To our knowledge, this is the first study describing a “disappearing polymorph” phenomenon of any pharmaceutically relevant transition metal coordination compound. Our findings may have significant implications for medicinal chemistry and pharmacology of coordination complexes, suggesting the need for systematic revision of historical crystallographic data in this field.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗

Gene and genome duplications have contrasting impacts on biosynthetic and flower developmental pathways in California poppy

Benzylisoquinoline alkaloids (BIAs) represent a vast group of specialized plant metabolites with diverse pharmaceutical applications, synthesized by a variety of gene families. Among the multiple plant lineages that produce BIAs, the most notable is the poppy family (Papaveraceae), with California poppy (Eschscholzia californica) emerging as a model organism. Here, we report a haplotype-resolved genome assembly, in combination with a high-density expression atlas, for California poppy. Genome analyses reveal recent diversification of BIA biosynthesis genes in poppy through localized duplications. Furthermore, we demonstrate that the degree of phylogenetic relatedness among paralogs within BIA biosynthesis-associated gene families correlates with similarities in gene expression. In contrast, gene families involved in carotenoid biosynthesis, which contributes to the intense orange petal pigmentation, are not phylogenetically clustered, and floral developmental regulators exhibit a high degree of retention of gene duplicates associated with ancient polyploidy events. These findings illustrate alternative roles for gene and genome duplications as drivers of trait evolution. Given the position of California poppy in the angiosperm phylogeny, the high-quality genomic resources generated for this work constitute a valuable resource for comparative genomic and transcriptomic analyses for poppies and flowering plants more generally.

Rössner, Le-Han [Justus-Liebig University, Giessen↗

EvoDiffMol: evolutionary diffusion framework for 3D molecular design with optimized properties

Designing molecules with specific target properties remains a fundamental challenge in computational chemistry. While existing approaches show promise, most rely on simplified representations like SMILES strings or 2D graphs that lack essential three-dimensional geometric information. We present EvoDiffMol, a computational framework that integrates evolutionary algorithms with three-dimensional diffusion models for property-driven molecular generation. The method operates through adaptive evolutionary optimization, where population-based selection guides the generation process toward desired property landscapes. EvoDiffMol supports both unconstrained molecular design and scaffold-constrained generation that preserves fixed substructures while optimizing complementary regions. Comprehensive evaluation demonstrates exceptional performance, achieving the highest drug-likeness score (0.94) among all compared state-of-the-art methods while maintaining excellent validity, uniqueness, and novelty. Beyond single property optimization, the framework demonstrates flexible multi-property optimization capabilities, simultaneously controlling multiple molecular descriptors including synthetic accessibility, lipophilicity, topological polar surface area, and clinically relevant ADMET properties such as cardiotoxicity (hERG) and intestinal permeability (Caco-2). This adaptability spans from simple descriptors to practical pharmaceutical endpoints without requiring complete model retraining. The framework achieves precise control over target property values, generating molecules with properties closely matching specified targets for both single and multiple descriptors. Scaffold-constrained experiments preserve fixed molecular cores while maintaining effective property optimization. The three-dimensional representation offers advantages in maintaining structural validity during iterative optimization, with potential for geometry-aware applications in materials science and drug discovery.

3D molecular generation↗

Microgravity Game Changers: Recent Accomplishments of Microgravity Assisted Materials Experiments on the ISS

This paper discusses important new materials, devices and technology produced in low-Earth orbit (LEO) that have been developed with funding from NASA’s In Space Production Applications (InSPA) Portfolio. In coordination with the International Space Station (ISS) National Laboratory, InSPA supports innovative small businesses and other research & development organizations to develop microgravity-assisted applications that make significant impacts in a wide variety of industries on Earth. These technology development efforts are using the microgravity of orbital space to overcome gravity-induced defects on Earth to create high-value products for terrestrial markets in the areas of semiconductors, pharmaceuticals, and communications. Through 24/7/365 operation on ISS for 25 years, coupled with commercial space transportation and services to, in, and from orbit, the microgravity environment has enabled pioneering science and significant commercial applications, including novel medical advances. World-leading researchers, innovators, and space payload developers provide compelling evidence through demonstrations on the ISS that materials processing in microgravity improves outcomes for a wide range of materials and products at all levels of the organization of matter, from quantum entities such as Bose-Einstein condensates, to crystals, alloys, composites, thin films, and photonics, to stem cells, medical diagnoses, medical treatments, and medical devices for humans. As of 2026, numerous examples proved by demonstration on ISS show the potential of these technologies in various fields. In this paper, a summary of four important experiments is presented.

microgravity medical devices↗

Innovation Concepts in Healthcare

Demographic change and advances in medical science pose increased challenges to healthcare systems globally: The economic basis is aging and thus health is becoming more and more a productivity factor. At the same time, with today’s new communication possibilities the demand and expectations of effective medical treatment have been increased. This presentation will illustrate the need for the “industrialization” of healthcare in order to achieve highest results at limited budgets. Thereby, industrialization is not meaning the medical treatment based on the assembly line approach. Rather it is to recognize the cost of medical care as an investment with respective expectations on the return of the investment. Innovations in imaging and pharmaceutical products as well as in processes - that lead to similar medical results, but with lower efforts - are keys in such scenarios. Biography Prof. Dr. Hermann Requardt, 54, is a member of the Managing Board of Siemens AG and Chief Executive Officer of the Healthcare Sector. In addition he is the CTO of Siemens AG and Head of Corporate Technology, the central research department at Siemens. After completing his studies in physics and philosophy at the Darmstadt University of Technology and Johann Wolfgang Goethe University in Frankfurt and receiving a doctorate in biophysics, he worked at the Institute of Aerospace Medicine at the German Aerospace Center.In 1984 he joined the Medical Technology Group of Siemens AG, where he was responsible for projects in the Magnetic Resonance (MR) division. He was appointed head of the division in 1995. From 2001 to 2006, as a member of the Executive Management of the Medical Solutions Group, he was responsible for several areas, including technological development.In 2006 he became a Member of the Siemens’ Managing Board and head of Corporate Technology. He was additionally appointed as the Sector Healthcare CEO in 2008.Since 2006 he is an honorary professor in physics of the Johann Wolfgang Goethe University in Frankfurt.

HEALTHCARE↗

X-ray Studies Key to Nobel Prize Winning Work on Protein Receptors

It was the advent of the first micro X-ray beam for structural biology at the Advanced Photon Source at Argonne National Laboratory that enabled the research that earned the 2012 Nobel Prize in Chemistry and lays the groundwork for countless new pharmaceuticals.

AMINO ACIDS↗

Drug Discovery

Sally Ellingson harnesses the massive power of supercomputing to seek the next generation of pharmaceuticals.

59 BASIC BIOLOGICAL SCIENCES↗

The Evolution of Randomized Clinical Trial Designs to Assess Therapeutics in Alzheimer Disease

Importance The success of recent randomized clinical trials (RCTs) for Alzheimer disease (AD), particularly those focusing on anti-amyloid therapies, has been discussed at length. However, the evolution of RCT design features for AD that preceded this success remain underexplored. Objective To describe temporal changes in the features of RCT design for interventions in AD. Evidence Review PubMed, Scopus, and Web of Science databases were searched in January 2025 for phase 2 and 3 AD RCTs published between January 1992 and December 2024. RCTs that investigated an intervention for AD, with a placebo or standard-of-care control group, were included. Four assessors independently reviewed full-text articles to capture study characteristics. Main Outcomes and Measures The number of participants and the duration of RCTs as well as the target population, outcomes, and funding were extracted from published reports. These features were analyzed with respect to time using linear regression and χ 2 analyses. Results The study included 203 RCTs with 79 589 participants testing interventions in AD. From 1992 to 2024, the mean sample size increased by 464% for phase 2 RCTs (from 42 to 237), and 50% for phase 3 RCTs (from 632 to 951), while the mean trial duration increased by 188% (from 16 to 46 weeks) for phase 2, and 256% (from 20 to 71 weeks) for phase 3 RCTs. This longer duration of RCTs may be partially attributed by a greater share of disease-modifying rather than symptomatic treatments. Similarly, more recent trials required AD biomarker evidence for enrollment (from 1 of 36 [2.7%] before 2006 to 40 of 76 [52.6%] since 2019). A substantial difference in the type of therapeutics researched was observed, with anti-amyloid and anti-tau RCTs being more likely to be funded by the pharmaceutical industry compared with neurotransmitter or other RCTs (anti-amyloid or anti-tau, 68 of 71 [95.8%]; neurotransmitter, 52 of 69 [77.6%]; other, 33 of 52 [63.5%]). RCT transparency improved, with more frequent data accessibility statements, registered reports, and better reporting on race and ethnicity. Conclusions and Relevance This methodology research of AD RCTs highlights substantial changes in key features of AD clinical trials from 1992 to 2024. AD RCTs have become larger and longer, such that they are powered to detect smaller clinical differences. The increased sample sizes and duration should enable the detection of smaller and more slowly occurring outcomes, which may lead to successful RCTs of therapies with slower and more subtle efficacy.

General & Internal Medicine↗

The E. coli L‐asparaginase V27T mutant: structural and functional characterization and comparison with theoretical predictions

Bacterial L‐asparaginases have been used for over 40 years as anticancer drugs. Ardalan et al. ( Medical Hypotheses 112, 7–17, 2018) proposed that the V27T mutant of Escherichia coli type II L‐asparaginase, EcAII(V27T), should display altered biophysical and catalytic properties compared to the wild‐type enzyme, EcAII(wt), rendering it more favourable as a pharmaceutical. They postulated that EcAII(V27T) would exhibit reduced glutaminolytic activity and be more stable compared to EcAII(wt). Their postulates, however, were purely theoretical. Here, we characterized experimentally selected properties of EcAII(V27T). We found asparaginolytic activity of this mutant unchanged, whereas its glutaminolytic activity was fourfold lower compared with EcAII(wt). We did not observe significant differences in stabilities of EcAII(wt) and EcAII(V27T). Crystal structures of the complexes with L‐Asp and L‐Glu showed considerable differences in binding modes of both substrates.

Biochemistry & Molecular Biology↗

Ion Mobility Spectrometry-Mass Spectrometry for High-Throughput Analysis

Ion mobility spectrometry is a widely used analytical technique providing gas phase separation of molecules. It has received increasing attention in the recent years with the advancement in technology development and the availability of commercial instruments. In this chapter, we introduced the ion mobility fundamental theory and provided examples of IMS applications, especially for isomer separation, collision cross section database generation, high throughput analysis workflows, software tools for IMS data analysis, and ongoing high resolution SLIM IMS development. While IMS is not yet routinely utilized in drug discovery and pharmaceutical industry, there has been increased interest in high throughput library screening and antibody characterization. With all the ongoing development in IMS technology and informatics, we foresee more and more exciting applications of high throughput IMS analysis in different fields including omics studies, drug discovery and clinical applications in the near future.

Ross, Dylan H.↗